Denmark-based healthcare foundation Novo and Lundbeckfond Ventures, owned by the Danish Lundbeck foundation, have backed US-based kidney treatment company AlloCure with $25m.
The two investors were joined by venture capital firm SV Life Sciences in AlloCure’s series B round. Mette Kirstine Agger, managing partner of Lundbeckfond Ventures, has joined AlloCure’s board. AlloCure was founded in 2006.
The latest round takes AlloCure to an estimated circa $48m raised in its history. Allocure raised $1.5m in debt and options last year, according to a Securities and Exchange Commission filing.
In 2009, it raised $5.6m, according to another filing. It also filed a planned $14.5m fundraising in 2008, which was reported as closing in various reports.
It also raised more than $2m in two other filings in 2008 and 2009.